



Review

Factors Affecting Metabolic Outcomes Post Bariatric Surgery: Role of Adipose Tissue

Sara H. Keshavjee ¹, Katherine J. P. Schwenger ², Jitender Yadav ³, Timothy D. Jackson ⁴, Allan Okrainec ⁴ and Johane P. Allard ^{2,*}

¹ Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; shk2176@cumc.columbia.edu

² Division of Gastroenterology, Toronto General Hospital, University Health Network, Toronto, ON M5G 2N2, Canada; kschweng@uhnresearch.ca

³ Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada; jitu.yadav@mail.utoronto.ca

⁴ Division of General Surgery, University Health Network, University of Toronto, Toronto, ON M5T 2S8, Canada; timothy.jackson@uhn.ca (T.D.J.); allan.okrainec@uhn.ca (A.O.)

* Correspondence: dr.johane.allard@uhn.ca

Abstract: Obesity is an ever-growing public health crisis, and bariatric surgery (BS) has become a valuable tool in ameliorating obesity, along with comorbid conditions such as diabetes, dyslipidemia and hypertension. BS techniques have come a long way, leading to impressive improvements in the health of the majority of patients. Unfortunately, not every patient responds optimally to BS and there is no method that is sufficient to pre-operatively predict who will receive maximum benefit from this surgical intervention. This review focuses on the adipose tissue characteristics and related parameters that may affect outcomes, as well as the potential influences of insulin resistance, BMI, age, psychologic and genetic factors. Understanding the role of these factors may help predict who will benefit the most from BS.

Keywords: bariatric surgery; adipose tissue; metabolic outcomes



Citation: Keshavjee, S.H.; Schwenger, K.J.P.; Yadav, J.; Jackson, T.D.; Okrainec, A.; Allard, J.P. Factors Affecting Metabolic Outcomes Post Bariatric Surgery: Role of Adipose Tissue. *J. Clin. Med.* **2021**, *10*, 714. <https://doi.org/10.3390/jcm10040714>

Academic Editor: David Benaiges Boix

Received: 15 January 2021

Accepted: 9 February 2021

Published: 11 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Obesity is an ever-growing problem and the World Health Organization estimated 650 million people to be obese in 2016 [1]. The main cause of obesity is the overconsumption of calories versus expenditure; however, other factors such as endocrine dysfunction, genetic makeup, and sleep debt can also contribute to obesity [2]. Along with obesity comes the burden of comorbidities, such as cardiovascular disease [3], diabetes [3], non-alcoholic fatty liver disease (NAFLD) [4], and hypertension (HTN) [5]. Specifically, obesity doubles the risk of HTN and triples the risk of type 2 diabetes mellitus (T2DM) in the 45–54 year old age category [6]. There is also a high prevalence of metabolic syndrome that accompanies obesity. Although criteria are controversial, someone is considered to have metabolic syndrome if they have three or more of the following: abdominal obesity, dyslipidemia, insulin resistance or hyperglycemia and HTN [7]. When compared to those of normal weight, individuals who are overweight have a 5.5-fold higher risk and individuals with obesity have a 32-fold higher risk of developing metabolic syndrome [8]. Despite this risk, not all individuals with obesity develop metabolic syndrome, and there is a stark contrast between those with “metabolically healthy” obesity versus “metabolically unhealthy” obesity. These relatively new categories of obesity came to light when noticing a subgroup of people with obesity, often early-onset, who have normal insulin sensitivity, and no signs of metabolic syndrome; “metabolically healthy” obesity [9]. Recently, the “metabolically healthy” obesity group has also been shown to have a decreased inflammatory state compared to similar-weight controls [10], and decreased liver fat content [11]. “Metabolically

unhealthy” obesity is associated with a higher incidence of HTN, insulin resistance, and dyslipidemia, while “metabolically healthy” individuals with obesity have a lower risk of these comorbidities, along with a lesser degree of adipose tissue dysfunction [12].

One particularly effective treatment for obesity and its comorbidities is bariatric surgery (BS), which may be accomplished by various techniques such as Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and biliopancreatic diversion with duodenal switch (BPD) [13]. BS has been shown to be effective for achieving significant weight loss, with an average of 28.6% total body weight loss following RYGB and 25% following laparoscopic SG at five years post-surgery [14].

In addition to the direct benefits of weight loss, BS has been shown to decrease the magnitude of comorbidities such as HTN [15,16] and dyslipidemia, and even cause remission of T2DM [14,17,18]. The improvement on the three aforementioned comorbidities after RYGB surgery has been shown to be superior to medical and lifestyle management in a randomized controlled trial (RCT) of 120 patients [16]. Another RCT of 150 patients showed that an endpoint of HbA1c <6% without the use of diabetes medication was met by 29% of participants that received RYGB and by 23% who received SG, compared to only 5% for conventional medical therapy [19].

Despite huge successes in weight loss and comorbidity reduction from BS, not every patient achieves the significant weight loss and/or metabolic improvements. Approximately 10–20% of BS patients have insufficient weight loss one year after surgery, with excess body weight loss <40% or total weight loss <20% [20]. Additionally, even when patients initially achieve weight loss and improvements in T2DM, these problems can recur [21]. The challenge remains in predicting which patients will benefit most from BS. In this review, we will be summarizing the known predictors of BS outcomes, with a focus on the influence that adipose tissue characteristics may have.

2. Predictors of Bariatric Surgery Outcome

The success of bariatric surgery is generally evaluated based on percent total or percent excess body weight loss (EBWL) and reduction of comorbidities such as HTN, dyslipidemia, insulin resistance or T2DM. When attempting to predict the probability of BS success, studies often assess the severity of obesity (BMI, waist-to-hip ratio), age, and comorbidities at baseline. There are many other factors that are more recently being considered, such as social and psychological factors, as well as characteristics of the adipose tissue itself. This review focuses on adipose tissue characteristics and related parameters that may affect outcomes as well as the potential influence of insulin resistance, BMI, age, psychological and genetic factors.

2.1. Adipose Tissue: Structure, Hypertrophy, Fibrosis

In obesity, as adipose tissue accommodates to caloric excess, it expands via hypertrophy or hyperplasia, to increase fatty acid storage [22]. This occurs in two main compartments: under the skin as the subcutaneous adipose tissue (SAT) or around abdominal organs as visceral adipose tissue (VAT). VAT includes the compartments of omental, retroperitoneal and mesenteric depots, each with varying metabolic properties [23]. Expansion of the visceral compartment is often associated with metabolically unhealthy obesity and development of comorbidities, whereas predominant SAT expansion is associated with metabolically healthy obesity [12]. Metabolic derangements and T2DM may be linked to VAT due to the fact that it is more metabolically active, and liver dysfunction can result from fatty acids, inflammatory cytokines and metabolites draining into portal circulation [24]. The visceral and subcutaneous fat is inherently different; subcutaneous fat confers fewer metabolic complications and may even be less harmful than VAT [25–27]. Adding to the complexity, even within one fat depot there are multiple subpopulations of adipocytes that have differing metabolic and physiological properties [28].

Clearly, expansion of adipose tissue is not benign in a patient with obesity. The depot of fat, along with method of expansion, has important effects on the development of

comorbidities, including metabolic syndrome. Particularly, expansion of adipose tissue through hypertrophy can be indicative of dysfunctional adipocytes, inflammation, and risk for visceral adipose deposition [29]. Some studies have shown that the degree of adipocyte hypertrophy may predict increased risk of T2DM and a lower probability of T2DM remission after BS [30]. Hypertrophy, as opposed to hyperplasia, is also associated with worse metabolic derangements, such as dyslipidemia [31]. Thus, looking at adipocyte hypertrophy may provide important insight into the outcome of BS, especially in individuals with T2DM.

Additionally, during obesity, important changes occur in the extracellular matrix (ECM) of adipose tissue. As adipose tissue expands, the ECM is degraded; however, long-term inflammation, including macrophage infiltration [32], leads to a switch toward fibrosis, restricting adipose expansion [33]. This limitation in adipose expansion is thought to play a role in increasing visceral adipose deposition. Specifically, individuals with obesity show increased fibrosis [34] and expression of ECM component genes (such as various integrins, collagens, glycosaminoglycans and proteoglycans) in SAT compared to lean controls, along with a similar trend in liver fibrosis [35]. This may be mediated by a shift in adipocyte precursor population to a CD9+ phenotype, which has a pro-fibrotic effect [36]. There is, however, some evidence to show that fibrosis is not purely maladaptive, as VAT fibrosis may be protective against adipocyte hypertrophy and the consequent metabolic derangements, such as T2DM [37]. A study of 82 individuals undergoing BS found that SAT and VAT ECM deposition was decreased in both VAT and SAT of patients with T2DM, when observed by sirius red staining [37]. Consistent with the possible protective role of fibrosis, this study found that VAT fibrotic gene expression was decreased among diabetic patients, with a correlation to HbA1c levels [37]. Fibrosis may also be harmful, as another study of 65 patients found that those with increased SAT fibrosis had poorer fat mass loss percentage after RYGB surgery [31]. It is possible that despite fibrotic VAT's protective effect on T2DM, there remains a detriment to weight loss following BS due to dysfunctional ECM remodeling. Overall, the fibrotic response may be indicative of the degree of inflammation and metabolic dysregulation, helping to predict outcomes after BS.

Changes in the adipose tissue architecture and lipid composition do occur after BS. One month following RYGB, patients' VAT was found to have decreased fat fraction and increased T1 relaxation time on MRI in comparison to before surgery [38]. The T1 time is negatively correlated with fat content [39], showing that this may be a more nuanced measurement to take into account aside from adipose tissue mass, especially in regards to visceral adiposity. As soon as four weeks after BS, SAT adipocyte size has been shown to decrease significantly, along with a decrease in E2F1 expression, a marker of proliferation [40]. Interestingly, another study has shown that the number of adipocyte precursor cells is increased following BS and weight loss as compared to pre-BS, where numbers of precursors are often low in patients with obesity [41]. At two years post-RYGB, women's fat cell volume was more closely associated with improved insulin sensitivity than reduction in fat mass [42]. This shows that the remodeling of the adipose tissue through fat content and adipocyte size may be a useful indicator of underlying metabolic changes, possibly returning the tissue to a metabolically healthy state. Associated changes may also occur in the ECM, as there is decreased expression of ECM component genes and increased expression of ECM degradation pathways (such as via metallopeptidases) in patients three months post-BS when compared to pre-operative levels [35]. Although gene expression shows anti-fibrotic changes after weight loss, there is debate as to whether existing fibrosis is reversible or not [35].

2.2. Adipose Tissue: Inflammatory Response

Numerous metabolic and inflammatory changes occur within expanding adipose tissue in a patient with obesity, which may contribute to development of comorbidities, including metabolic syndrome. As a result of the stress-induced changes, obesity has come to be considered a form of chronic inflammatory disease, driven by the close interactions

of adipocytes and adipose tissue macrophages (ATM) [43]. These changes in adipose tissue are significant, and it is of interest to find out whether the varying inflammatory phenotypes of adipose tissue correlate to the varying outcomes of BS procedures.

Expansion of adipose tissue can lead to tissue hypoperfusion and hypoxia [44]. This makes hypoxic markers a promising area of research for predicting adipose tissue dysfunction. This hypoxia and adipose tissue stress causes a change in released adipokines, becoming more pro-inflammatory via IL-1 β , IL-6, TNF, IL-8, leptin, resistin and MCP-1 [45]. This causes the recruitment of monocytes and as obesity progresses, ATM have been shown to progress from predominantly M2 to M1 type, assuming a more pro-inflammatory phenotype [46]. Aside from M1 and M2, some macrophages may take on an entirely different phenotype in obesity, the metabolically activated macrophage, which contributes to both inflammation and clearance of dead adipocytes [47].

The overall increase of inflammatory cytokines, as mentioned above, contributes to insulin resistance through a variety of mechanisms [48]. Specifically, expression of IL-6 from adipose tissue is elevated in obesity, with a threefold higher expression in omental fat as opposed to subcutaneous fat [49]. IL-6 can induce expression of C reactive protein (CRP), which are together used as clinical markers of inflammation and risk of T2DM development, independent of obesity [50,51]. TNF- α , produced by macrophages, has also been targeted as a link between obesity and insulin resistance, as a TNF- α antagonist Etanercept causes improvements in fasting blood glucose levels in obese individuals with metabolic syndrome [52]. TNF- α has also been shown to be an antagonist of GLUT4, a key mechanism of glucose uptake in response to insulin [53]. Additionally, MCP-1 expression has been shown to be elevated in SAT in obese individuals [54], along with elevations in those with T2DM without obesity [55]. MCP-1 likely has a direct role in insulin resistance, as mouse models with MCP-1 deletions are protected from high-fat diet induced insulin resistance and have less macrophage infiltration in adipose tissue [56]. However, MCP-1 may have broad-reaching effects, as MCP-1 knockout mice also had protection from hepatic steatosis during high-fat diet induced obesity [56]. Taken together, markers of inflammation along with insulin resistance measurements may help to predict chance of T2DM remission and outcomes after BS.

Many changes have been seen to occur in the inflammatory response following BS. At the tissue level, there is a decrease in subcutaneous ATMs after BS and weight loss, with an increase in IL-10 cytokine expression, signaling a shift to an anti-inflammatory M2 phenotype [57]. Multiple studies have shown a decrease in M1 and increase in M2 macrophages [58] appearing within three months post-BS [59]. However, the omental adipose tissue macrophages are likely the most important to assess, as they may be largely responsible for metabolic derangements. Canello et al. found twice the number of ATMs in omental versus subcutaneous fat, with only omental macrophage counts correlating to insulin resistance and hepatic fibroinflammatory lesions [60]. Another contributing factor to the inflammatory profile improvement after BS is that hypoxic dysfunction of adipose tissue was shown to be reduced, including a reduction in hypoxic marker HIF-1 α , macrophage chemo-attractants (MCP-1, CSF-3, PLAU), and macrophage numbers [57]. On a systemic level, a meta-analysis of 116 studies showed that circulating levels of inflammatory markers like IL-6, TNF- α , and CRP significantly decreased following BS, which is in line with other studies on traditional weight loss [57]. Therefore, the reduction in inflammation following BS may be a product of the weight loss rather than the surgery itself [61,62].

The change in adipose tissue mass and degree of inflammation post-BS may be predicted by pre-surgical systemic and adipose-specific markers. When looking at predicting BS outcome, higher pre-operative systemic CRP levels have been shown to be associated with increased weight loss post-BS [63]. Another study found that high hs-CRP in women is able to predict the degree of reduction in visceral fat area one year post-surgery [64]. In general, a study of 37 patients undergoing BS found that an increase in adipose tissue inflammatory response (as measured by CD11b and IL-10 mRNA expression in adipose tissue) was associated with lower BMI loss after BS [65]. When looking broadly at the

level of the serum proteome, Wewer Albrechtsen et al. found that 88 proteins changed significantly from baseline when measured again one week after surgery [66]. Many of the implicated proteins are important in inflammatory processes (complement, acute phase proteins, CRP) or lipid homeostasis [66]. Some proteins showed changes up to two years later, which may illustrate the difference between rapid surgery-induced effects and long-term weight loss-induced effects. Although the changes of inflammatory markers in response to BS have been researched, the role for many of these markers in predicting BS outcomes remains to be studied. Certain markers, such as circulating hs-CRP and tissue IL-10, may be implicated in predicting BS response, but there remains large potential for research regarding the use of inflammatory markers.

2.3. Adipose Tissue: Adipokine Dysregulation

As adipose tissue expands in obesity, the cells experience hypertrophy, along with oxidative and inflammatory stressors. This leads many individuals with obesity to experience altered adipokine secretion from adipose tissue, which can have far-reaching effects on the body and metabolism. In Table 1, we will briefly review the function of the main adipokines and their relationship to metabolic syndrome, followed by the effect of BS.

Table 1. Adipokines implicated in obesity and changes noted post-bariatric surgery (BS).

| Adipokine | Role in Obesity Pathogenesis | Changes after BS |
|-------------|---|--|
| Leptin | <ul style="list-style-type: none"> • ↑ with degree of adiposity [67], signals hypothalamus to ↑ energy expenditure, ↓ hunger [68]. • Pro-inflammatory effect on macrophages (increased TNF-α and IL-6), induces a Th1 cell inflammatory phenotype, releasing IL-2 and IFN-γ [50]. • Leptin resistance may occur in obesity, for a variety of reasons [69–71]. • Patients with increased circulating leptin pre-BS have increased weight loss post-BS [64]. However, other smaller studies have not found the same association [72]. | <p>↓ systemic leptin concentrations following various types of BS and weight loss [58,73].</p> |
| Adiponectin | <ul style="list-style-type: none"> • Functions in anti-apoptotic signaling, ↓inflammation, ↓insulin sensitivity [74]. ↓macrophage activation, ↑IL-10 production [50]. • Levels are inversely correlated with adiposity [75] and degree of dysfunction in adipocytes [76]. • Serum adiponectin <4.0 $\mu\text{g}/\text{mL}$ greatly increases the likelihood of metabolic syndrome [77], can also be correlated with probability of developing T2DM [78]. • Study of BS recipients (n = 1570) found that pre-BS adiponectin levels were not useful in predicting BS outcomes [79]. | <p>↑ circulating adiponectin within three months post-BS [80].</p> <p>↑ adiponectin adipose tissue expression with levels similar to normal weight controls within two years post-BS [81].</p> |
| Resistin | <ul style="list-style-type: none"> • ↑IR, ↑hepatic glucose production, ↑inflammation (via monocyte secretion of IL6, TNF) [50]. • Role in IR due to its stimulation of SOCS3 expression, which inhibits insulin signaling in the adipocyte [82] • Some studies show levels to be predictive of T2DM progression [83,84], where others have shown it to be associated with increased BMI rather than insulin resistance [85,86]. • Inflammatory role—correlates with circulating CRP, IL-6 and TNF-α levels in patients with inflammatory diseases or T2DM [87]. • Dyslipidemia—positive correlation with VLDL, and negative with HDL [87]. | <p>↓ in SAT expression 12 months post-BS [81]. However, results are conflicting [73].</p> |

Table 1. Cont.

| Adipokine | Role in Obesity Pathogenesis | Changes after BS |
|----------------------------------|--|---|
| Retinol Binding Protein 4 (RBP4) | <ul style="list-style-type: none"> • Main protein to which retinol (vitamin A) binds to in serum, produced by liver and adipose tissue. • ↑IR, which may be due to RBPP4's negative correlation with GLUT4, which is necessary to import glucose into cells to be metabolized [88] • ↑ Serum levels in obesity, associated with metabolic syndrome and T2DM [89]. • Adipose tissue expression levels associated with ↑ BMI, waist circumference, circulating RBP4 and HOMA IR [90]. • Dysregulated levels (high or low) are predictive of T2DM risk, independent of BMI [91]. | ↓ RBP4 in 12 months following BS, with a correlation to decreases in fasting glucose, serum triglycerides, and weight [92]. |

Along with the aforementioned adipokines in Table 1, many others have been studied and shown to have dysfunctional expression in obesity. These include visfatin [93], chemerin, lipocalin-2 [94], CXCL5, IL-18, and NAMPT [50], among others. Another area of interest regarding adipose tissue is that white adipose tissue, typically seen in obesity, [95] can change its phenotype into brown-like adipose tissue, called beige/brite adipose tissue, which is associated with improvements in IR, reduction in blood glucose and increased resting energy expenditure [96–98]. The increase in thermogenic capacity is mediated by UCP1 (uncoupling protein 1) [99,100], which is highly induced in brown-like adipocytes and expressed in the inner membrane of the mitochondria [95]. The transcription of UCP1 requires critical co-activators, specifically PGC1- α and PPAR γ which commit the cells to thermogenesis [101,102]. This is of interest as recent research showed a decrease in functional brown adipose tissue in obesity [103].

In summary, analysis of adipokine levels pre-operatively may give insight into the degree of metabolic derangement and inflammation that is present in patients undergoing BS, while post-operative measures may track improvement in metabolic parameters. Although some adipokines have been shown to aid in BS outcome prediction as mentioned above, the role of others remains unclear.

2.4. Insulin Resistance and Type 2 Diabetes Mellitus

T2DM is a common phenomenon in individuals with obesity, as there is an association between obesity and insulin resistance in skeletal muscle, liver, and adipose tissue [104], along with pancreatic beta cell dysfunction [105]. T2DM remission often occurs after BS, especially from surgeries with a malabsorptive component; the highest remission rates occur after BPD (95%) and second-highest from RYGB (75%) [106]. However, remission after surgery is less likely in patients with poor glycemic control and increasing time since diabetes diagnosis, likely due to more extensive pancreatic beta cell damage and dysfunction [19,107].

A common clinical test for insulin resistance is the homeostatic model assessment for insulin resistance (HOMA-IR). HOMA-IR is generally increased in individuals with increased weight or obesity, and it is associated with T2DM and cardiometabolic complications [108]. In those with obesity, high HOMA-IR is also associated with steatosis and liver fibrosis [109]. Additionally, the probability of T2DM remission in the long and short term after RYGB surgery can be estimated with a DiaREM score, taking into account age, HbA1c and diabetes medication use [110,111]. Through predicting insulin resistance severity, these scores may help predict BS-related improvements in glycemic control.

Within one week after RYGB, before significant weight loss, patients experience improvements in glucose homeostasis [112]. This may be attributed to hepatic insulin sensitivity increase, as seen in one study measuring this via basal glucose and basal hepatic insulin sensitivity index [112]. Quick changes in insulin sensitivity following surgery may be due to calorie restriction after surgery, leading to reduced hepatic fat

and subsequent insulin sensitivity increases [112,113]. Within one week, there are also increases in postprandial GLP-1 secretion, which enhances pancreatic beta cell function by stimulating insulin release [114]. One study using diet-induced obese rats found that the response to GLP-1 agonists has been shown to predict the efficacy of RYGB on glucose tolerance [115]. A recent study in T2DM individuals undergoing RYGB surgery found that those who experienced T2DM remission one year post-RYGB had significantly higher pre-RYGB GLP-1 concentrations [116]. However, research is limited and the degree in which GLP-1 predicts metabolic success post-RYGB is still contested [117]. In addition to GLP-1, HOMA_IR score has also been shown to decrease as soon as two weeks after surgery [118]. In the longer term, peripheral insulin resistance has been shown to improve by three months post-BS [119]. This may be mediated in part by continually decreasing intramyocellular fat [120], causing increased insulin sensitivity of skeletal muscle [121]. In another study, MRI analysis showed hepatic fat was reduced below the pathological range by six months and pancreatic fat 12 months post-BS, further explaining the long-term improvement in insulin resistance [122]. The beneficial effects of BS on the liver extend past insulin resistance, as a meta-analysis of 15 studies found that non-alcoholic steatohepatitis was resolved in 69.5% of cases and steatosis was improved in approximately 91.6% of cases [123]. There is evidence that surgeries with a malabsorptive component, such as RYGB, have better outcomes in terms of diabetes remission and improved HOMA-IR score than simply restrictive surgery in both short and long term [19,124–127]. In summary, there appears to be a role for using diabetes status and time since diagnosis to predict remission following BS, but its role in predicting weight loss and other metabolic parameters following BS remains to be studied.

2.5. BMI, Pre-Operative Weight Loss

Pre-operative BMI does seem to be an important predictor of BS results. Using a database of over seventy-thousand BS recipients, pre-operative weight has been shown to account for a large portion, approximately 18.5%, of the variation seen in weight loss post-BS [128]. Additionally, a meta-analysis has shown that many studies observed a lower EBWL percentage in those with a higher pre-operative BMI [129]. These results may be due to the fact that those with higher BMI are more likely to have the burden of comorbidities [130], including metabolic syndrome [8]. Along with BMI, surgery type is a major predictor of weight loss outcomes, explaining approximately 44.8% of the variability in a study of patients receiving RYGB, adjustable gastric band, or SG [128]. Evidently, BMI may be a major predictor in explaining BS outcome, and together with surgery type, these factors may explain a large portion of outcome variability.

The use of preoperative weight loss as a mandatory criterion before BS is a widely debated topic, with evidence for and against its utility. A study of the Swedish national registry for BS ($n = 9570$) found that there was a strong positive association between pre- and post-operative weight loss, especially in those in the highest BMI quartile [131]. Other studies saw similar data, such as a study of 884 patients undergoing RYGB that found those who achieved 10% EBWL preoperatively, were more likely to attain the goal of 70% EBWL post-BS [132]. A recent study of 355 RYGB or SG recipients asked patients to maintain a low calorie diet with the goal of 8% EBWL for four weeks before BS [133]. Those who achieved $\geq 8\%$ EBWL had significantly greater EBWL at three, six and twelve months post-BS than those who did not achieve 8% EBWL pre-operatively [133]. Although many studies show a positive association between pre- and post-operative weight loss, it is difficult to tease out the impact of the pre-operative weight loss itself versus individual reactions to caloric restriction, along with the surgical candidate selection factors associated with mandatory preoperative EBWL.

2.6. Age

Along with the aforementioned factors, the age of the patient has been shown to have an effect on BS outcomes. In addition to having a negative impact on weight loss,

higher age carries a higher risk of intraoperative and post-operative complications, which must be factored into the risk-benefit analysis of recommending BS. Some studies have reported significantly more complications in the older age group compared to those below 60 [134]. However, a recent study on more than three thousand patients undergoing RYGB or laparoscopic SG found no increase in intra-operative or post-operative complications for the 60+ age group [135]. Other studies have also found that EBWL is negatively affected by increasing age, including a study of more than thirteen-hundred patients aged 18–65 undergoing RYGB or SG [136].

2.7. Psychological Factors

Although many predictors of surgery outcome are not modifiable, some of the psychiatric conditions that correlate with poor outcome can be controlled and ameliorated before surgery. Patients with psychiatric disorders before SG surgery, such as personality disorders, adjustment disorders or depression, have been shown to have worse outcomes than those without mental illness [137]. Importantly, worse outcomes have been shown even in individuals with past mood disorders and no current episode, highlighting the possible role of additional treatment and social support before and after surgery in any patient with current or past mental health concerns [138].

2.8. Genetic Factors

Recently, studies have begun to look at how an individual's genotype may be able to predict their response to BS. Many genome wide association studies have shown that there are hundreds of heritable genes that correlate with phenotypes such as waist-to-hip ratio and BMI [139]. Some alleles are even associated with a more metabolically healthy obese picture, with decreased comorbidities such as HTN, T2DM and heart disease [140]. When trying to analyze whether single nucleotide polymorphisms (SNPs) are associated with weight loss after RYGB, a genome wide association study by Rinella et al. found that genetic variants clustering around the genes of PKHD1, HTR1A, GUCY1A2, NMBR, KCNK2 and IGF1R may be implicated [141]. These genes have previously been related to biological processes such as appetite, lipid and glucose homeostasis and early onset obesity [141]. Similar results were seen in a study by Aasbrenn et al. [142]. Paradoxically, Aasbrenn et al. also noticed that individuals genetically predisposed to "slimness" experienced significantly poorer weight loss after surgery, possibly signaling social rather than biological causes of obesity in these patients [142]. In the future, genetic testing for SNPs may be used to predict a portion of one's variable outcome after BS.

3. Conclusions

BS and the associated weight loss improve many metabolic and inflammatory parameters associated with changes in adipose tissue, adipokine expression, inflammatory profile and glucose/lipid homeostasis. The adipose tissue phenotype itself is very closely linked to the comorbidities that develop in individuals with obesity and their response to BS. Among pre-BS factors that may predict outcomes post-BS, those that have been found to be significant from the adipose tissue are VAT/SAT fibrosis, circulating CRP, Cd11b and IL10 adipose tissue mRNA levels, and possibly circulating leptin. In addition, other significant factors include diabetes status and time since diagnosis, pre-operative weight loss, age and psychological disorders. There may be other factors that can predict post-BS response, including a variety of adipokines and inflammatory markers (both circulating and expressed in adipose tissue), but further studies will be required in order to determine their significance. In the future, clinicians can use pre-operative data to better predict patient outcomes post-BS, as well as determine the optimal treatment plan for their patients.

Author Contributions: Writing—original draft preparation, S.H.K.; writing—review and editing, K.J.P.S., J.Y., T.D.J., A.O. and J.P.A.; supervision, K.J.P.S., J.Y., T.D.J., A.O. and J.P.A.; project administration, K.J.P.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: S.H.K., K.J.P.S., J.Y., T.D.J. and J.P.A. have no conflict of interest to declare. Author 5 (A.O.) has relevant financial activities outside of the submitted work. He is provided an honorarium for speaking and teaching from Ethicon, Medtronic and Merk. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. WHO. Obesity and Overweight. 2020. Available online: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> (accessed on 1 September 2020).
2. Keith, S.W.; Redden, D.T.; Katzmarzyk, P.T.; Boggiano, M.M.; Hanlon, E.C.; Benca, R.M.; Ruden, D.; Pietrobelli, A.; Barger, J.L.; Fontaine, K.R.; et al. Putative contributors to the secular increase in obesity: Exploring the roads less traveled. *Int. J. Obes.* **2006**, *30*, 1585–1594. [[CrossRef](#)]
3. Singh, G.M.; Danaei, G.; Farzadfar, F.; Stevens, G.A.; Woodward, M.; Wormser, D.; Kaptoge, S.; Whitlock, G.; Qiao, Q.; Lewington, S.; et al. The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis. *PLoS ONE* **2013**, *8*, e65174. [[CrossRef](#)] [[PubMed](#)]
4. Li, L.; Liu, D.W.; Yan, H.Y.; Wang, Z.Y.; Zhao, S.H.; Wang, B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies. *Obes. Rev.* **2016**, *17*, 510–519. [[CrossRef](#)] [[PubMed](#)]
5. Wang, Y.; Wang, Q.J. The prevalence of prehypertension and hypertension among US Adults According to the New Joint National Committee Guidelines: New challenges of the old problem. *Arch. Intern. Med.* **2004**, *164*, 2126–2134. [[CrossRef](#)] [[PubMed](#)]
6. Thompson, D.; Edelsberg, J.; Colditz, G.A.; Bird, A.P.; Oster, G. Lifetime health and economic consequences of obesity. *Arch. Intern. Med.* **1999**, *159*, 2177–2183. [[CrossRef](#)] [[PubMed](#)]
7. Grundy, S.M.; Brewer, H.B.; Cleeman, J.I.; Smith, S.C.; Lenfant, C. Definition of Metabolic Syndrome. *Arterioscler. Thromb. Vasc. Biol.* **2004**, *24*, 2. [[CrossRef](#)] [[PubMed](#)]
8. Johnson, W.D.; Kroon, J.J.M.; Greenway, F.L.; Bouchard, C.; Ryan, D.; Katzmarzyk, P.T. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001–2006. *Arch. Pediatr. Adolesc. Med.* **2009**, *163*, 371–377. [[CrossRef](#)]
9. Sims, E.A.H. Are there persons who are obese, but metabolically healthy? *Metabolism* **2001**, *50*, 1499–1504. [[CrossRef](#)] [[PubMed](#)]
10. Shin, M.J.; Hyun, Y.J.; Kim, O.Y.; Kim, J.Y.; Jang, Y.; Lee, J.H. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: Low inflammation and LDL oxidation in MHO women. *Int. J. Obes.* **2006**, *30*, 1529–1534. [[CrossRef](#)]
11. Stefan, N.; Kantartzis, K.; Machann, J.; Schick, F.; Thamer, C.; Rittig, K.; Balletshofer, B.; Machicao, F.; Fritsche, A.; Häring, H.U. Identification and characterization of metabolically benign obesity in humans. *Arch. Intern. Med.* **2008**, *168*, 1609–1616. [[CrossRef](#)]
12. Iacobini, C.; Pugliese, G.; Blasetti Fantauzzi, C.; Federici, M.; Menini, S. Metabolically healthy versus metabolically unhealthy obesity. *Metabolism* **2019**, *92*, 51–60. [[CrossRef](#)] [[PubMed](#)]
13. Nguyen, N.T.; Varela, J.E. Bariatric surgery for obesity and metabolic disorders: State of the art. *Nat. Rev. Gastroenterol. Hepatol.* **2017**, *14*, 160–169. [[CrossRef](#)]
14. Peterli, R.; Wolnerhanssen, B.K.; Peters, T.; Vetter, D.; Kroll, D.; Borbely, Y.; Schultes, B.; Beglinger, C.; Drewe, J.; Schiesser, M.; et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass on weight loss in patients with morbid obesity the sm-boss randomized clinical trial. *JAMA J. Am. Med. Assoc.* **2018**, *319*, 255–265. [[CrossRef](#)]
15. Owen, J.G.; Yazdi, F.; Reisin, E. Bariatric Surgery and Hypertension. *Am. J. Hypertens.* **2018**, *31*, 11–17. [[CrossRef](#)]
16. Ikramuddin, S.; Korner, J.; Lee, W.-J.; Connett, J.E.; Inabnet III, W.B.; Billington, C.B.; Thomas, A.J.; Leslie, D.B.; Chong, K.; Jeffery, R.W.; et al. Roux-en-Y Gastric Bypass versus Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension and Hyperlipidemia: An International, Multicenter, Randomized Trial. *JAMA* **2013**, *309*, 2240–2249. [[CrossRef](#)]
17. Mingrone, G.; Panunzi, S.; De Gaetano, A.; Guidone, C.; Iaconelli, A.; Nanni, G.; Castagneto, M.; Bornstein, S.; Rubino, F. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet* **2015**, *386*, 964–973. [[CrossRef](#)]
18. Guidone, C.; Manco, M.; Valera-Mora, E.; Iaconelli, A.; Gniuli, D.; Mari, A.; Nanni, G.; Castagneto, M.; Calvani, M.; Mingrone, G. Mechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery. *Diabetes* **2006**, *55*, 2025–2031. [[CrossRef](#)] [[PubMed](#)]
19. Schauer, P.R.; Bhatt, D.L.; Kirwan, J.P.; Wolski, K.; Aminian, A.; Brethauer, S.A.; Navaneethan, S.D.; Singh, R.P.; Pothier, C.E.; Nissen, S.E.; et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. *N. Engl. J. Med.* **2017**, *376*, 641–651. [[CrossRef](#)]

20. Nielsen, M.S.; Christensen, B.J.; Schmidt, J.B.; Tækker, L.; Holm, L.; Lunn, S.; Ritz, C.; Wewer Albrechtsen, N.J.; Holst, J.J.; Schnurr, T.M.; et al. Predictors of weight loss after bariatric surgery—A cross-disciplinary approach combining physiological, social, and psychological measures. *Int. J. Obes.* **2020**, *44*, 2291–2302. [[CrossRef](#)]
21. Digiorgi, M.; Rosen, D.J.; Choi, J.J.; Milone, L.; Schrope, B.; Olivero-Rivera, L.; Restuccia, N.; Yuen, S.; Fisk, M.; Inabnet, W.B.; et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. *Surg. Obes. Relat. Dis.* **2010**, *6*, 249–253. [[CrossRef](#)] [[PubMed](#)]
22. Wang, Q.A.; Tao, C.; Gupta, R.K.; Scherer, P.E. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. *Nat. Med.* **2013**, *19*, 1338–1344. [[CrossRef](#)] [[PubMed](#)]
23. Frikke-Schmidt, H.; O'Rourke, R.W.; Lumeng, C.N.; Sandoval, D.A.; Seeley, R.J. Does bariatric surgery improve adipose tissue function? *Obes. Rev.* **2016**, *17*, 795–809. [[CrossRef](#)] [[PubMed](#)]
24. Rytka, J.M.; Wueest, S.; Schoenle, E.J.; Konrad, D. The portal theory supported by venous drainage-selective fat transplantation. *Diabetes* **2011**, *60*, 56–63. [[CrossRef](#)] [[PubMed](#)]
25. Tran, T.T.; Yamamoto, Y.; Gesta, S.; Kahn, C.R. Beneficial Effects of Subcutaneous Fat Transplantation on Metabolism. *Cell Metab.* **2008**, *7*, 410–420. [[CrossRef](#)] [[PubMed](#)]
26. Vishvanath, L.; Gupta, R.K. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. *J. Clin. Investig.* **2019**, *129*, 4022–4031. [[CrossRef](#)]
27. Fox, C.S.; Massaro, J.M.; Hoffmann, U.; Pou, K.M.; Maurovich-Horvat, P.; Liu, C.-Y.; Vasan, R.S.; Murabito, J.M.; Meigs, J.B.; Cupples, L.A.; et al. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments. *Circulation* **2007**, *116*, 39–48. [[CrossRef](#)] [[PubMed](#)]
28. Lee, K.Y.; Luong, Q.; Sharma, R.; Dreyfuss, J.M.; Ussar, S.; Kahn, C.R. Developmental and functional heterogeneity of white adipocytes within a single fat depot. *EMBO J.* **2019**, *38*, e99291. [[CrossRef](#)]
29. Gustafson, B.; Hammarstedt, A.; Hedjazifar, S.; Smith, U. Restricted adipogenesis in hypertrophic obesity: The role of WISP2, WNT, and BMP4. *Diabetes* **2013**, *62*, 2997–3004. [[CrossRef](#)]
30. Cotillard, A.; Poitou, C.; Torcivia, A.; Bouillot, J.-L.; Dietrich, A.; Klötting, N.; Grégoire, C.; Lolmede, K.; Blüher, M.; Clément, K. Adipocyte Size Threshold Matters: Link with Risk of Type 2 Diabetes and Improved Insulin Resistance After Gastric Bypass. *J. Clin. Endocrinol. Metab.* **2014**, *99*, E1466–E1470. [[CrossRef](#)]
31. Divoux, A.; Tordjman, J.; Lacasa, D.; Veyrie, N.; Hugol, D.; Aissat, A.; Basdevant, A.; Guerre-Millo, M.; Poitou, C.; Zucker, J.D.; et al. Fibrosis in human adipose tissue: Composition, distribution, and link with lipid metabolism and fat mass loss. *Diabetes* **2010**, *59*, 2817–2825. [[CrossRef](#)]
32. Keophiphath, M.; Achard, V.; Henegar, C.; Rouault, C.; Clément, K.; Lacasa, D. Le Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. *Mol. Endocrinol.* **2009**, *23*, 11–24. [[CrossRef](#)]
33. Crewe, C.; An, Y.A.; Scherer, P.E. The ominous triad of adipose tissue dysfunction: Inflammation, fibrosis, and impaired angiogenesis. *J. Clin. Investig.* **2017**, *127*, 74–82. [[CrossRef](#)] [[PubMed](#)]
34. Chabot, K.; Gauthier, M.-S.; Garneau, P.Y.; Rabasa-Lhoret, R. Evolution of subcutaneous adipose tissue fibrosis after bariatric surgery. *Diabetes Metab.* **2017**, *43*, 125–133. [[CrossRef](#)] [[PubMed](#)]
35. Henegar, C.; Tordjman, J.; Achard, V.; Lacasa, D.; Cremer, I.; Guerre-Millo, M.; Poitou, C.; Basdevant, A.; Stich, V.; Viguerie, N.; et al. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. *Genome Biol.* **2008**, *9*, R14. [[CrossRef](#)]
36. Marcelin, G.; Ferreira, A.; Liu, Y.; Atlan, M.; Aron-Wisnewsky, J.; Pelloux, V.; Botbol, Y.; Ambrosini, M.; Fradet, M.; Rouault, C.; et al. A PDGFR α -Mediated Switch toward CD9high Adipocyte Progenitors Controls Obesity-Induced Adipose Tissue Fibrosis. *Cell Metab.* **2017**, *25*, 673–685. [[CrossRef](#)]
37. Muir, L.A.; Neeley, C.K.; Meyer, K.A.; Baker, N.A.; Brosius, A.M.; Washabaugh, A.R.; Varban, O.A.; Finks, J.F.; Zamarron, B.F.; Flesher, C.G.; et al. Adipose tissue fibrosis, hypertrophy, and hyperplasia: Correlations with diabetes in human obesity. *Obesity* **2016**, *24*, 597–605. [[CrossRef](#)]
38. Lehmann, S.; Linder, N.; Retschlag, U.; Schaudinn, A.; Stange, R.; Garnov, N.; Dietrich, A.; Oberbach, A.; Kahn, T.; Busse, H. MRI assessment of changes in adipose tissue parameters after bariatric surgery. *PLoS ONE* **2018**, *13*, e0206735. [[CrossRef](#)]
39. Scholz, T.D.; Fleagle, S.R.; Parrish, F.C.; Breon, T.; Skorton, D.J. Effect of tissue fat and water content on nuclear magnetic resonance relaxation times of cardiac and skeletal muscle. *Magn. Reson. Imaging* **1990**, *8*, 605–611. [[CrossRef](#)]
40. Katsogiannos, P.; Kamble, P.G.; Boersma, G.J.; Karlsson, F.A.; Lundkvist, P.; Sundbom, M.; Pereira, M.J.; Eriksson, J.W. Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D. *J. Clin. Endocrinol. Metab.* **2019**, *104*, 2601–2613. [[CrossRef](#)]
41. García-Rubio, J.; León, J.; Redruello-Romero, A.; Pavón, E.; Cozar, A.; Tamayo, F.; Caba-Molina, M.; Salmerón, J.; Carazo, Á. Cytometric analysis of adipose tissue reveals increments of adipocyte progenitor cells after weight loss induced by bariatric surgery. *Sci. Rep.* **2018**, *8*, 1–12. [[CrossRef](#)] [[PubMed](#)]
42. Andersson, D.P.; Hogling, D.E.; Thorell, A.; Toft, E.; Qvisth, V.; Näslund, E.; Thörne, A.; Wirén, M.; Löfgren, P.; Hoffstedt, J.; et al. Changes in subcutaneous fat cell volume and insulin sensitivity after weight loss. *Diabetes Care* **2014**, *37*, 1831–1836. [[CrossRef](#)] [[PubMed](#)]
43. Hotamisligil, G.S. Inflammation and metabolic disorders. *Nature* **2006**, *444*, 860–867. [[CrossRef](#)] [[PubMed](#)]

44. Hosogai, N.; Fukuhara, A.; Oshima, K.; Miyata, Y.; Tanaka, S.; Segawa, K.; Furukawa, S.; Tochino, Y.; Komuro, R.; Matsuda, M.; et al. Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation. *Diabetes* **2007**, *56*, 901–911. [[CrossRef](#)] [[PubMed](#)]
45. Kusminski, C.M.; Bickel, P.E.; Scherer, P.E. Targeting adipose tissue in the treatment of obesity-associated diabetes. *Nat. Rev. Drug Discov.* **2016**, *15*, 639. [[CrossRef](#)]
46. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J. Clin. Invest.* **2007**, *117*, 175–184. [[CrossRef](#)] [[PubMed](#)]
47. Shumer, D.E.; Nokoff, N.J. Metabolically activated adipose tissue macrophages perform detrimental and beneficial functions during diet-induced obesity. *Physiol. Behav.* **2017**, *176*, 139–148.
48. Ni, Y.; Ni, L.; Zhuge, F.; Xu, L.; Fu, Z.; Ota, T. Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders. *Obesity* **2020**, *28*, 225–234. [[CrossRef](#)]
49. Fried, S.K.; Bunkin, D.A.; Greenberg, A.S. Omental and Subcutaneous Adipose Tissues of Obese Subjects Release Interleukin-6: Depot Difference and Regulation by Glucocorticoid. *J. Clin. Endocrinol. Metab.* **1998**, *83*, 847–850. [[CrossRef](#)]
50. Ouchi, N.; Parker, J.L.; Lugus, J.J.; Walsh, K. Adipokines in inflammation and metabolic disease. *Nat. Rev. Immunol.* **2011**, *11*, 85–97. [[CrossRef](#)]
51. Kanmani, S.; Kwon, M.; Shin, M.K.; Kim, M.K. Association of C-Reactive Protein with Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A Large Population-Based Korean Cohort Study. *Sci. Rep.* **2019**, *9*, 1–8. [[CrossRef](#)]
52. Stanley, T.L.; Zanni, M.V.; Johnsen, S.; Rasheed, S.; Makimura, H.; Lee, H.; Khor, V.K.; Ahima, R.S.; Grinspoon, S.K. TNF- α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. *J. Clin. Endocrinol. Metab.* **2011**, *96*, E146–E150. [[CrossRef](#)] [[PubMed](#)]
53. Lumeng, C.N.; Deyoung, S.M.; Saltiel, A.R. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. *Am. J. Physiol. Endocrinol. Metab.* **2007**, *292*, E166. [[CrossRef](#)] [[PubMed](#)]
54. Murdolo, G.; Hammarstedt, A.; Sandqvist, M.; Schmelz, M.; Herder, C.; Smith, U.; Jansson, P.A. Monocyte chemoattractant protein-1 in subcutaneous abdominal adipose tissue: Characterization of interstitial concentration and regulation of gene expression by insulin. *J. Clin. Endocrinol. Metab.* **2007**, *92*, 2688–2695. [[CrossRef](#)] [[PubMed](#)]
55. Mine, S.; Okada, Y.; Tanikawa, T.; Kawahara, C.; Tabata, T.; Tanaka, Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. *Biochem. Biophys. Res. Commun.* **2006**, *344*, 780–785. [[CrossRef](#)] [[PubMed](#)]
56. Kanda, H.; Tateya, S.; Tamori, Y.; Kotani, K.; Hiasa, K.; Kitazawa, R.; Kitazawa, S.; Miyachi, H.; Maeda, S.; Egashira, K.; et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity1. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, others. MCP-1 contributes to m. *J. Clin. Invest.* **2006**, *116*, 1494. [[CrossRef](#)]
57. Canello, R.; Henegar, C.; Viguier, N.; Taleb, S.; Poitou, C.; Rouault, C.; Coupaye, M.; Pelloux, V.; Hugol, D.; Bouillot, J.L.; et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes* **2005**, *54*, 2277–2286. [[CrossRef](#)]
58. Labrecque, J.; Laforest, S.; Michaud, A.; Biertho, L.; Tchernof, A. Impact of Bariatric Surgery on White Adipose Tissue Inflammation. *Can. J. Diabetes* **2017**, *41*, 407–417. [[CrossRef](#)]
59. Liu, Y.; Aron-Wisnewsky, J.; Marcelin, G.; Genser, L.; Le Naour, G.; Torcivia, A.; Bauvois, B.; Bouchet, S.; Pelloux, V.; Sasso, M.; et al. Accumulation and Changes in Composition of Collagens in Subcutaneous Adipose Tissue After Bariatric Surgery. *J. Clin. Endocrinol. Metab.* **2016**, *101*, 293–304. [[CrossRef](#)] [[PubMed](#)]
60. Canello, R.; Tordjman, J.; Poitou, C.; Guilhem, G.; Bouillot, J.L.; Hugol, D.; Coussieu, C.; Basdevant, A.; Hen, A.B.; Bedossa, P.; et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. *Diabetes* **2006**, *55*, 1554–1561. [[CrossRef](#)]
61. Askarpour, M.; Khani, D.; Sheikhi, A.; Ghaedi, E.; Alizadeh, S. Effect of Bariatric Surgery on Serum Inflammatory Factors of Obese Patients: A Systematic Review and Meta-Analysis. *Obes. Surg.* **2019**, *29*, 2631–2647. [[CrossRef](#)]
62. Canello, R.; Clément, K. Review article: Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. *BJOG Int. J. Obstet. Gynaecol.* **2006**, *113*, 1141–1147. [[CrossRef](#)]
63. O'Rourke, R.W.; Johnson, G.S.; Purnell, J.Q.; Courcoulas, A.P.; Dakin, G.F.; Garcia, L.; Hinojosa, M.; Mitchell, J.E.; Pomp, A.; Pories, W.J.; et al. Serum biomarkers of inflammation and adiposity in the LABS cohort: Associations with metabolic disease and surgical outcomes. *Int. J. Obes.* **2019**, *43*, 285–296. [[CrossRef](#)]
64. Carbone, F.; Nulli Migliola, E.; Bonaventura, A.; Vecchié, A.; De Vuono, S.; Ricci, M.A.; Vaudo, G.; Boni, M.; Dallegri, F.; Montecucco, F.; et al. High serum levels of C-reactive protein (CRP) predict beneficial decrease of visceral fat in obese females after sleeve gastrectomy. *Nutr. Metab. Cardiovasc. Dis.* **2018**, *28*, 494–500. [[CrossRef](#)]
65. Lasselin, J.; Magne, E.; Beau, C.; Ledaguenel, P.; Dexpert, S.; Aubert, A.; Layé, S.; Capuron, L. Adipose Inflammation in Obesity: Relationship With Circulating Levels of Inflammatory Markers and Association With Surgery-Induced Weight Loss. *J. Clin. Endocrinol. Metab.* **2014**, *99*, E53–E61. [[CrossRef](#)]
66. Wewer Albrechtsen, N.J.; Geyer, P.E.; Doll, S.; Treit, P.V.; Bojsen-Møller, K.N.; Martinussen, C.; Jørgensen, N.B.; Torekov, S.S.; Meier, F.; Niu, L.; et al. Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. *Cell Syst.* **2018**, *7*, 601–612.e3. [[CrossRef](#)]

67. Considine, R.V.; Sinha, M.K.; Heiman, M.L.; Kriauciunas, A.; Stephens, T.W.; Nyce, M.R.; Ohannesian, J.P.; Marco, C.C.; Mckee, L.J.; Bauer, T.L.; et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N. Engl. J. Med.* **1996**, *334*, 292–295. [[CrossRef](#)] [[PubMed](#)]
68. Münzberg, H.; Morrison, C.D. Structure, production and signaling of leptin. *Metabolism* **2015**, *64*, 13–23. [[CrossRef](#)]
69. Martin, T.L.; Alquier, T.; Asakura, K.; Furukawa, N.; Preitner, F.; Kahn, B.B. Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. *J. Biol. Chem.* **2006**, *281*, 18933–18941. [[CrossRef](#)] [[PubMed](#)]
70. Jung, C.H.; Kim, M.S. Molecular mechanisms of central leptin resistance in obesity. *Arch. Pharm. Res.* **2013**, *36*, 201–207. [[CrossRef](#)] [[PubMed](#)]
71. Ozcan, L.; Ergin, A.S.; Lu, A.; Chung, J.; Sarkar, S.; Nie, D.; Myers, M.G.; Ozcan, U. Endoplasmic Reticulum Stress Plays a Central Role in Development of Leptin Resistance. *Cell Metab.* **2009**, *9*, 35–51. [[CrossRef](#)] [[PubMed](#)]
72. Czupryniak, L.; Pawlowski, M.; Kumor, A.; Szymanski, D.; Loba, J.; Strzelczyk, J. Predicting maximum Roux-en-Y gastric bypass-induced weight reduction—Preoperative plasma leptin or body weight? *Obes. Surg.* **2007**, *17*, 162–167. [[CrossRef](#)] [[PubMed](#)]
73. Askarpour, M.; Alizadeh, S.; Hadi, A.; Symonds, M.E.; Miraghajani, M.; Sheikhi, A.; Ghaedi, E. Effect of Bariatric Surgery on the Circulating Level of Adiponectin, Chemerin, Plasminogen Activator Inhibitor-1, Leptin, Resistin, and Visfatin: A Systematic Review and Meta-Analysis. *Horm. Metab. Res.* **2020**, *52*, 207–215. [[CrossRef](#)] [[PubMed](#)]
74. Turer, A.T.; Scherer, P.E. Adiponectin: Mechanistic insights and clinical implications. *Diabetologia* **2012**, *55*, 2319–2326. [[CrossRef](#)]
75. Matsubara, M.; Maruoka, S.; Katayose, S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. *Eur. J. Endocrinol.* **2002**, *147*, 173–180. [[CrossRef](#)] [[PubMed](#)]
76. Meyer, L.K.; Ciaraldi, T.P.; Henry, R.R.; Wittgrove, A.C.; Phillips, S.A. Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. *Adipocyte* **2013**, *2*, 217–226. [[CrossRef](#)] [[PubMed](#)]
77. Ryo, M.; Nakamura, T.; Kihara, S.; Kumada, M.; Shibazaki, S.; Takahashi, M.; Nagai, M.; Matsuzawa, Y.; Funahashi, T. Adiponectin as a biomarker of the metabolic syndrome. *Circ. J.* **2004**, *68*, 975–981. [[CrossRef](#)]
78. Mather, K.J.; Goldberg, R.B. Clinical Use of Adiponectin as a Marker of Metabolic Dysregulation. *Best Pract. Res. Clin. Endocrinol. Metab.* **2014**, *28*, 107–117. [[CrossRef](#)]
79. Herder, C.; Peltonen, M.; Svensson, P.A.; Carstensen, M.; Jacobson, P.; Roden, M.; Sjöström, L.; Carlsson, L. Adiponectin and bariatric surgery: Associations with diabetes and cardiovascular disease in the Swedish obese subjects study. *Diabetes Care* **2014**, *37*, 1401–1409. [[CrossRef](#)]
80. Wolf, R.M.; Jaffe, A.E.; Steele, K.E.; Schweitzer, M.A.; Magnuson, T.H.; Wolfe, A.; Wong, G.W. Cytokine, Chemokine, and Cytokine Receptor Changes Are Associated with Metabolic Improvements after Bariatric Surgery. *J. Clin. Endocrinol. Metab.* **2018**, *104*, 947–956. [[CrossRef](#)]
81. Haluzíková, D.; Lacinová, Z.; Kaválková, P.; Drápalová, J.; Křížová, J.; Bártlová, M.; Mráz, M.; Petr, T.; Vítek, L.; Kasalický, M.; et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. *Obesity* **2013**, *21*, 1335–1342. [[CrossRef](#)]
82. Steppan, C.M.; Wang, J.; Whiteman, E.L.; Birnbaum, M.J.; Lazar, M.A. Activation of SOCS-3 by Resistin. *Mol. Cell. Biol.* **2005**, *25*, 1569–1575. [[CrossRef](#)]
83. Chen, B.H.; Song, Y.; Ding, E.L.; Roberts, C.K.; Manson, J.E.; Rifai, N.; Buring, J.E.; Gaziano, J.M.; Liu, S. Circulating levels of resistin and risk of type 2 diabetes in men and women: Results from two prospective cohorts. *Diabetes Care* **2009**, *32*, 329–334. [[CrossRef](#)]
84. Heidemann, C.; Sun, Q.; Van Dam, R.M.; Meigs, J.B.; Zhang, C.; Tworoger, S.S.; Mantzoros, C.S.; Hu, F.B. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. *Ann. Intern. Med.* **2008**, *149*, 307–316. [[CrossRef](#)]
85. Panidis, D.; Koliakos, G.; Kourtis, A.; Farmakiotis, D.; Mouslech, T.; Rousso, D. Serum resistin levels in women with polycystic ovary syndrome. *Fertil. Steril.* **2004**, *81*, 361–366. [[CrossRef](#)] [[PubMed](#)]
86. Laudes, M.; Oberhauser, F.; Schulte, D.M.; Freude, S.; Bilkovski, R.; Mauer, J.; Rapp, G.; Abken, H.; Hahn, M.; Schulz, O.; et al. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. *Horm. Metab. Res.* **2010**, *42*, 268–273. [[CrossRef](#)] [[PubMed](#)]
87. Park, H.K.; Kwak, M.K.; Kim, H.J.; Ahima, R.S. Linking resistin, inflammation, and cardiometabolic diseases. *Korean J. Intern. Med.* **2017**, *32*, 239–247. [[CrossRef](#)] [[PubMed](#)]
88. Yang, Q.; Graham, T.E.; Mody, N.; Preitner, F.; Peroni, O.D.; Zabolotny, J.M.; Kotani, K.; Quadro, L.; Kahn, B.B. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* **2005**, *436*, 356–362. [[CrossRef](#)] [[PubMed](#)]
89. Graham, T.E.; Yang, Q.; Blüher, M.; Hammarstedt, A.; Ciaraldi, T.P.; Henry, R.R.; Wason, C.J.; Oberbach, A.; Jansson, P.A.; Smith, U.; et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. *N. Engl. J. Med.* **2006**, *354*, 2552–2563. [[CrossRef](#)]
90. Lu, H.-Y.; Li, X.-F.; Mu, P.-W.; Jiang, W.; Zheng, L.-Y. Depot-specific Expression of Retinol-Binding Protein 4 in Human Adipose Tissue and Their Relationship With Obesity and Insulin Resistance. *Zhonghua Yi Xue Za Zhi* **2010**, *90*, 3395–3398.
91. Fan, J.; Yin, S.; Lin, D.; Liu, Y.; Chen, N.; Bai, X.; Ke, Q.; Shen, J.; You, L.; Lin, X.; et al. Association of serum retinol-binding protein 4 levels and the risk of incident type 2 diabetes in subjects with prediabetes. *Diabetes Care* **2019**, *42*, 1574–1581. [[CrossRef](#)]

92. Broch, M.; Gómez, J.M.; Auguet, M.T.; Vilarrasa, N.; Pastor, R.; Elio, I.; Olona, M.; García-España, A.; Richart, C. Association of retinol-binding protein-4 (RBP4) with lipid parameters in obese women. *Obes. Surg.* **2010**, *20*, 1258–1264. [[CrossRef](#)] [[PubMed](#)]
93. Terra, X.; Auguet, T.; Quesada, I.; Aguilar, C.; Luna, A.M.; Hernández, M.; Sabench, F.; Porras, J.A.; Martínez, S.; Lucas, A.; et al. Increased levels and adipose tissue expression of visfatin in morbidly obese women: The relationship with pro-inflammatory cytokines. *Clin. Endocrinol.* **2012**, *77*, 691–698. [[CrossRef](#)] [[PubMed](#)]
94. Unamuno, X.; Gómez-Ambrosi, J.; Rodríguez, A.; Becerril, S.; Frühbeck, G.; Catalán, V. Adipokine dysregulation and adipose tissue inflammation in human obesity. *Eur. J. Clin. Investig.* **2018**, *48*, e12997. [[CrossRef](#)]
95. Vargas-Castillo, A.; Fuentes-Romero, R.; Rodríguez-Lopez, L.A.; Torres, N.; Tovar, A.R. Understanding the Biology of Thermogenic Fat: Is Browning A New Approach to the Treatment of Obesity? *Arch. Med. Res.* **2017**, *48*, 401–413. [[CrossRef](#)] [[PubMed](#)]
96. Ouellet, V.; Labbé, S.M.; Blondin, D.P.; Phoenix, S.; Guérin, B.; Haman, F.; Turcotte, E.E.; Richard, D.; Carpentier, A.C. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. *J. Clin. Investig.* **2012**, *122*, 545–552. [[CrossRef](#)] [[PubMed](#)]
97. Kajimura, S.; Spiegelman, B.M.; Seale, P. Brown and beige fat: Physiological roles beyond heat generation. *Cell Metab.* **2015**, *22*, 546–559. [[CrossRef](#)]
98. Ballestri, S.; Nascimbeni, F.; Baldelli, E.; Marrazzo, A.; Romagnoli, D.; Lonardo, A. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. *Adv. Ther.* **2017**, *34*, 1291–1326. [[CrossRef](#)]
99. Wu, J.; Boström, P.; Sparks, L.M.; Ye, L.; Choi, J.H.; Giang, A.H.; Khandekar, M.; Virtanen, K.A.; Nuutila, P.; Schaart, G.; et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell* **2012**, *150*, 366–376. [[CrossRef](#)]
100. Lidell, M.E.; Betz, M.J.; Enerbäck, S. Two types of brown adipose tissue in humans. *Adipocyte* **2014**, *3*, 63–66. [[CrossRef](#)]
101. Tai, T.A.C.; Jennermann, C.; Brown, K.K.; Oliver, B.B.; MacGinnitie, M.A.; Wilkison, W.O.; Roger Brown, H.; Lehmann, J.M.; Kliewer, S.A.; Morris, D.C.; et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. *J. Biol. Chem.* **1996**, *271*, 29909–29914. [[CrossRef](#)] [[PubMed](#)]
102. Puigserver, P.; Wu, Z.; Park, C.W.; Graves, R.; Wright, M.; Spiegelman, B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* **1998**, *92*, 829–839. [[CrossRef](#)]
103. Ghosh, P.M.; Shu, Z.J.; Zhu, B.; Lu, Z.; Ikeno, Y.; Barnes, J.L.; Yeh, C.K.; Zhang, B.X.; Katz, M.S.; Kamat, A. Role of β -adrenergic receptors in regulation of hepatic fat accumulation during aging. *J. Endocrinol.* **2012**, *213*, 251–261. [[CrossRef](#)] [[PubMed](#)]
104. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J. Clin. Investig.* **2003**, *112*, 1821–1830. [[CrossRef](#)] [[PubMed](#)]
105. Wong, V.W.-S.; Wong, G.L.-H.; Yeung, D.K.-W.; Abrigo, J.M.; Kong, A.P.-S.; Chan, R.S.-M.; Chim, A.M.-L.; Shen, J.; Ho, C.-S.; Woo, J.; et al. Fatty Pancreas, Insulin Resistance, and β -Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. *Am. J. Gastroenterol.* **2014**, *109*, 589–597. [[CrossRef](#)]
106. Mingrone, G.; Panunzi, S.; De Gaetano, A.; Guidone, C.; Iaconelli, A.; Leccesi, L.; Nanni, G.; Pomp, A.; Castagneto, M.; Ghirlanda, G.; et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. *N. Engl. J. Med.* **2012**, *366*, 1577–1585. [[CrossRef](#)]
107. Jans, A.; Nä Slund Id, I.; Ottosson Id, J.; Szabo, E.; Nä Slund Id, E.; Stenbergid, E. Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007–2015: A registry-based cohort study. *PLoS Med.* **2019**, *16*, e1002985. [[CrossRef](#)]
108. Shashaj, B.; Luciano, R.; Contoli, B.; Morino, G.S.; Spreghini, M.R.; Rustico, C.; Sforza, R.W.; Dallapiccola, B.; Manco, M. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. *Acta Diabetol.* **2016**, *53*, 251–260. [[CrossRef](#)] [[PubMed](#)]
109. Aller, R.; De Luis, D.; Pacheco, D.; Velasco, M.C.; Izaola, O.; Sagrado, M.G. Insulin resistance predicts steatosis and fibrosis in morbidly obese patients undergoing bariatric surgery. *J. Investig. Med.* **2012**, *60*, 1005–1008. [[CrossRef](#)]
110. Still, C.D.; Wood, G.C.; Benotti, P.; Petrick, A.T.; Gabrielsen, J.; Strodel, W.E.; Ibele, A.; Seiler, J.; Irving, B.A.; Celaya, M.P.; et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: A retrospective cohort study. *Lancet Diabetes Endocrinol.* **2014**, *2*, 38–45. [[CrossRef](#)]
111. Mehaffey, J.H.; Mullen, M.G.; Mehaffey, R.L.; Turrentine, F.E.; Malin, S.K.; Kirby, J.L.; Schirmer, B.; Hallowell, P.T. Type 2 diabetes remission following gastric bypass: Does diarem stand the test of time? *Surg. Endosc.* **2017**, *31*, 538–542. [[CrossRef](#)]
112. Bojsen-Møller, K.N.; Dirksen, C.; Jørgensen, N.B.; Jacobsen, S.H.; Serup, A.K.; Albers, P.H.; Hansen, D.L.; Worm, D.; Naver, L.; Kristiansen, V.B.; et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. *Diabetes* **2014**, *63*, 1725–1737. [[CrossRef](#)]
113. Lim, E.L.; Hollingsworth, K.G.; Aribisala, B.S.; Chen, M.J.; Mathers, J.C.; Taylor, R. Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* **2011**, *54*, 2506–2514. [[CrossRef](#)] [[PubMed](#)]
114. Jørgensen, N.B.; Dirksen, C.; Bojsen-Møller, K.N.; Jacobsen, S.H.; Worm, D.; Hansen, D.L.; Kristiansen, V.B.; Naver, L.; Madsbad, S.; Holst, J.J. Exaggerated glucagon-like peptide 1 response is important for improved β -cell function and glucose tolerance after roux-en-Y gastric bypass in patients with type 2 diabetes. *Diabetes* **2013**, *62*, 3044–3052. [[CrossRef](#)] [[PubMed](#)]

115. Habegger, K.M.; Heppner, K.M.; Amburgy, S.E.; Ottaway, N.; Holland, J.; Raver, C.; Bartley, E.; Müller, T.D.; Pfluger, P.T.; Berger, J.; et al. GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. *Diabetes* **2014**, *63*, 505–513. [[CrossRef](#)]
116. Izaguirre, M.; Gómez-Ambrosi, J.; Rodríguez, A.; Ramírez, B.; Becerril, S.; Valenti, V.; Moncada, R.; Unamuno, X.; Silva, C.; de la Higuera, M.; et al. GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients. *J. Clin. Med.* **2019**, *8*, 479. [[CrossRef](#)]
117. Hutch, C.R.; Sandoval, D. The role of GLP-1 in the metabolic success of bariatric surgery. *Endocrinology* **2017**, *158*, 4139–4151. [[CrossRef](#)]
118. Sridharan, K.; Kalayarasan, R.; Kamalanathan, S.; Sahoo, J.; Kar, S.S.; Nandhini, L.P.; Palui, R.; Durgina, H. Change in insulin resistance, beta cell function, glucagon-like peptide-1 and calcitonin levels two weeks after bariatric surgery. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2019**, *13*, 2142–2147. [[CrossRef](#)]
119. Martinussen, C.; Bojsen-Møller, K.N.; Dirksen, C.; Jacobsen, S.H.; Jørgensen, N.B.; Kristiansen, V.B.; Holst, J.J.; Madsbad, S. Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. *Am. J. Physiol. Metab.* **2015**, *308*, E535–E544. [[CrossRef](#)]
120. Toro-Ramos, T.; Goodpaster, B.H.; Janumala, I.; Lin, S.; Strain, G.W.; Thornton, J.C.; Kang, P.; Courcoulas, A.P.; Pomp, A.; Gallagher, D. Continued loss in visceral and intermuscular adipose tissue in weight-stable women following bariatric surgery. *Obesity* **2015**, *23*, 62–69. [[CrossRef](#)] [[PubMed](#)]
121. Greco, A.V.; Mingrone, G.; Giancaterini, A.; Manco, M.; Morroni, M.; Cinti, S.; Granzotto, M.; Vettor, R.; Camastra, S.; Ferrannini, E. Insulin resistance in morbid obesity: Reversal with intramyocellular fat depletion. *Diabetes* **2002**, *51*, 144–151. [[CrossRef](#)] [[PubMed](#)]
122. Hui, S.C.N.; Wong, S.K.H.; Ai, Q.; Yeung, D.K.W.; Ng, E.K.W.; Chu, W.C.W. Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: Evaluation with MRI. *Eur. Radiol.* **2019**, *29*, 849–856. [[CrossRef](#)] [[PubMed](#)]
123. Mummadi, R.R.; Kasturi, K.S.; Chennareddygar, S.; Sood, G.K. Effect of Bariatric Surgery on Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. *Clin. Gastroenterol. Hepatol.* **2008**, *6*, 1396–1402. [[CrossRef](#)] [[PubMed](#)]
124. Kashyap, S.R.; Daud, S.; Kelly, K.R.; Gastaldelli, A.; Win, H.; Brethauer, S.; Kirwan, J.P.; Schauer, P.R. Acute effects of gastric bypass versus gastric restrictive surgery on B-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. *Int. J. Obes.* **2010**, *34*, 462–471. [[CrossRef](#)] [[PubMed](#)]
125. Pournaras, D.J.; Osborne, A.; Hawkins, S.C.; Vincent, R.P.; Mahon, D.; Ewings, P.; Ghatei, M.A.; Bloom, S.R.; Welbourn, R.; Le Roux, C.W. Remission of type 2 diabetes after gastric bypass and banding: Mechanisms and 2 year outcomes. *Ann. Surg.* **2010**, *252*, 966–971. [[CrossRef](#)] [[PubMed](#)]
126. Lima, M.M.O.; Pareja, J.C.; Alegre, S.M.; Geloneze, S.R.; Kahn, S.E.; Astiarraga, B.D.; Chaim, É.A.; Geloneze, B. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: A study with the euglycemic-hyperinsulinemic clamp. *J. Clin. Endocrinol. Metab.* **2010**, *95*, 3871–3875. [[CrossRef](#)] [[PubMed](#)]
127. McTigue, K.M.; Wellman, R.; Nauman, E.; Anau, J.; Coley, R.Y.; Odor, A.; Tice, J.; Coleman, K.J.; Courcoulas, A.; Pardee, R.E.; et al. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass the national patient-centered clinical research network (PCORNet) bariatric study. *JAMA Surg.* **2020**, *155*, 1–12. [[CrossRef](#)]
128. Benoit, S.C.; Hunter, T.D.; Francis, D.M.; De La Cruz-Munoz, N. Use of Bariatric outcomes longitudinal database (BOLD) to study variability in patient success after Bariatric surgery. *Obes. Surg.* **2014**, *24*, 936–943. [[CrossRef](#)]
129. Livhits, M.; Mercado, C.; Yermilov, I.; Parikh, J.A.; Dutton, E.; Mehran, A.; Ko, C.Y.; Gibbons, M.M. Preoperative predictors of weight loss following bariatric surgery: Systematic review. *Obes. Surg.* **2012**, *22*, 70–89. [[CrossRef](#)]
130. Nickel, F.; De La Garza, J.R.; Werthmann, F.S.; Benner, L.; Tapking, C.; Karadza, E.; Wekerle, A.L.; Billeter, A.T.; Kenngott, H.G.; Fischer, L.; et al. Predictors of Risk and Success of Obesity Surgery. *Obes. Facts* **2019**, *12*, 427–439. [[CrossRef](#)]
131. Gerber, P.; Anderin, C.; Gustafsson, U.O.; Thorell, A. Weight loss before gastric bypass and postoperative weight change: Data from the Scandinavian Obesity Registry (SOReg). *Surg. Obes. Relat. Dis.* **2016**, *12*, 556–562. [[CrossRef](#)]
132. Still, C.D.; Benotti, P.; Wood, G.C.; Gerhard, G.S.; Petrick, A.; Reed, M.; Strodel, W. Outcomes of preoperative weight loss in high-risk patients undergoing gastric bypass surgery. *Arch. Surg.* **2007**, *142*, 994–998. [[CrossRef](#)]
133. Hutcheon, D.A.; Hale, A.L.; Ewing, J.A.; Miller, M.; Couto, F.; Bour, E.S.; Cobb, W.S.; Scott, J.D. Short-Term Preoperative Weight Loss and Postoperative Outcomes in Bariatric Surgery. *J. Am. Coll. Surg.* **2018**, *226*, 514–524. [[CrossRef](#)] [[PubMed](#)]
134. Benaiges, D.; Goday, A.; Pedro-Botet, J.; Mas, A.; Chillaron, J.; Flores-Le-Roux, J. Bariatric surgery: To whom and when? *Minerva Endocrinol.* **2012**, *147*, 135–140.
135. Kaplan, U.; Penner, S.; Farrokhyar, F.; Andruszkiewicz, N.; Breau, R.; Gmora, S.; Hong, D.; Anvari, M. Bariatric Surgery in the Elderly Is Associated with Similar Surgical Risks and Significant Long-Term Health Benefits. *Obes. Surg.* **2018**, *28*, 2165–2170. [[CrossRef](#)] [[PubMed](#)]
136. Contreras, J.E.; Santander, C.; Court, I.; Bravo, J. Correlation between age and weight loss after bariatric surgery. *Obes. Surg.* **2013**, *23*, 1286–1289. [[CrossRef](#)] [[PubMed](#)]
137. Kinzl, J.F.; Schrattenecker, M.; Traweger, C.; Mattesich, M.; Fiala, M.; Biebl, W. Psychosocial predictors of weight loss after bariatric surgery. *Obes. Surg.* **2006**, *16*, 1609–1614. [[CrossRef](#)] [[PubMed](#)]
138. Kalarchian, M.A.; Marcus, M.D.; Levine, M.D.; Soulakova, J.N.; Courcoulas, A.P.; Wisinski, M.S.C. Relationship of psychiatric disorders to 6-month outcomes after gastric bypass. *Surg. Obes. Relat. Dis.* **2008**, *4*, 544–549. [[CrossRef](#)] [[PubMed](#)]

139. Goodarzi, M.O. Genetics of obesity: What genetic association studies have taught us about the biology of obesity and its complications. *Lancet Diabetes Endocrinol.* **2018**, *6*, 223–236. [[CrossRef](#)]
140. Yaghootkar, H.; Lotta, L.A.; Tyrrell, J.; Smit, R.A.J.; Jones, S.E.; Donnelly, L.; Beaumont, R.; Campbell, A.; Tuke, M.A.; Hayward, C.; et al. Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart disease. *Diabetes* **2016**, *65*, 2448–2460. [[CrossRef](#)]
141. Rinella, E.S.; Still, C.; Shao, Y.; Wood, G.C.; Chu, X.; Salerno, B.; Gerhard, G.S.; Ostrer, H. Genome-wide association of single-nucleotide polymorphisms with weight loss outcomes after Roux-en-Y gastric bypass surgery. *J. Clin. Endocrinol. Metab.* **2013**, *98*, 1131–1136. [[CrossRef](#)]
142. Aasbrenn, M.; Schnurr, T.M.; Have, C.T.; Svendstrup, M.; Hansen, D.L.; Worm, D.; Balslev-Harder, M.; Hollensted, M.; Grarup, N.; Burgdorf, K.S.; et al. Genetic Determinants of Weight Loss After Bariatric Surgery. *Obes. Surg.* **2019**, *29*, 2554–2561. [[CrossRef](#)] [[PubMed](#)]